title: Therapeutic nanoparticles in clinics and under clinical evaluation.
abstract: This article reviews nanoparticulate-chemotherapeutic systems that have been developed for human therapy, considering the components of the nanoparticles, the therapeutic agents associated with the nanoparticles and the clinical indications these therapeutic nanoparticles have been developed for. In this evaluation we have put into perspective the types of nanomaterials and their therapeutic indications. We have reviewed the nanoparticulate-chemotherapeutic systems that have been published, approved and marketed and that are currently in clinical use. We have also analyzed the nanoparticulate-chemotherapeutic systems that are in clinical trials and under preclinical development.
authors.affiliation: Institut Universitaire de Pathologie/CHUV/UNIL, Rue du Bugnon 25, 1011 Lausanne, Switzerland.
authors.forename: Catherine A
authors.initials: CA
authors.lastname: Schütz
authors.forename: Lucienne
authors.initials: L
authors.lastname: Juillerat-Jeanneret
authors.forename: Heinz
authors.initials: H
authors.lastname: Mueller
authors.forename: Iseult
authors.initials: I
authors.lastname: Lynch
authors.forename: Michael
authors.initials: M
authors.lastname: Riediker
mesh_terms: D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems / Q000009:adverse effects*; D004353:Drug Evaluation, Preclinical; D004358:Drug Therapy; D006046:Gold / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D053768:Metal Nanoparticles / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D006046:Gold